Proteonomix Announces Agreement with the University of Medicine & Dentistry of New Jersey (UMDNJ) to Conduct a Phase 1 Trial ...
2012年9月14日 - 10:00PM
ビジネスワイヤ（英語）
Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company
focused on developing therapeutics based upon the use of human
cells and their derivatives, today announced it has entered into an
agreement with Piscataway, N.J.-based University of Medicine and
Dentistry of New Jersey (UMDNJ) to conducted a Phase 1 clinical
trial with its proprietary, patent-pending mobilization technology
UMK-121 in patients with end-stage liver disease (ESLD). The
Company also announced that Chief Executive Officer Michael Cohen
made a presentation at the National Investment Banking
Association’s (NIBA) 123rd Investment Conference yesterday at the
New York Marriott Downtown in New York City.
The single-center Phase 1 clinical trial, Mobilization of Stem
Cells with UMK 121 in Patients with Cirrhosis, will enroll 15
patients with ESLD. The trial will study the safety of mobilization
of stem cells in this patient population, as well as the effects of
mobilization of stems cells from bone marrow to the peripheral
circulation on liver function. Baburao Koneru, M.D., Professor and
Chief of the Division of Transplant and Hepatobiliary Surgery at
New Jersey Medical School, will serve as the trial’s principal
investigator.
“We are extremely pleased to announce that our trial will be
conducted at this highly respected institution under the direction
of Dr. Koneru, who is a renowned expert in the field of liver
function,” said Mr. Cohen. “Our presentation to the investment
professionals attending the NIBA conference provided an opportunity
to discuss the potential of UMK-121 in ESLD as we make preparations
to commence this clinical trial, which we hope to initiate in the
coming months.”
UMK-121 combines two existing FDA-approved drugs with the
intention of mobilizing mesenchymal stem cells from bone marrow to
the peripheral circulation. This proprietary drug combination is
designed to reduce inflammation and increase angiogenesis to
restore liver function, potentially extending the life of ESLD
patients awaiting liver transplant.
About the University of Medicine and Dentistry of New
Jersey
The University of Medicine and Dentistry of New Jersey (UMDNJ)
is New Jersey’s only health sciences university with more than
6,000 students on five campuses attending three medical schools,
the State’s only dental school, a graduate school of biomedical
sciences, a school of health related professions, a school of
nursing and New Jersey’s only school of public health. UMDNJ
operates University Hospital, a Level I Trauma Center in Newark,
and University Behavioral HealthCare, which provides a continuum of
healthcare services with multiple locations throughout the
State.
About National Investment Banking Association (NIBA)
NIBA is the only national not-for-profit trade association of
regional and independent brokerages, investment banking firms,
institutional investors and related capital market service
providers. Since its inception, NIBA member firms have successfully
completed more than 1,000 equity offerings totaling approximately
$10 billion in new capital. The member firms of NIBA represent more
than 8,000 registered representatives with an estimated $78 billion
in assets under management, and are responsible for 90% of all
Initial Public Offerings under $20 million. For more information,
please visit www.nibanet.org.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and plans to file an IND
application for treatment of patients who have suffered
post-myocardial infarction. Proteonomix Regenerative Translational
Medicine Institute, Inc. (PRTMI) intends to focus on the
translation of promising research in stem cell biology and cellular
therapy to clinical applications of regenerative medicine.
Additional information is available at www.proteonomix.com and
www.proteoderm.com.
Certain statements contained herein are
"forward-looking statements" (as defined in the Private Securities
Litigation Reform Act of 1995). Proteonomix, Inc. cautions that
statements made in this press release constitute forward-looking
statements and makes no guarantee of future performance. Actual
results or developments may differ materially from projections.
Forward-looking statements are based on estimates and opinions of
management at the time statements are made.
Proteonomix (CE) (USOTC:PROT)
過去 株価チャート
から 12 2024 まで 1 2025
Proteonomix (CE) (USOTC:PROT)
過去 株価チャート
から 1 2024 まで 1 2025
